Journal of Cardiovascular Translational Research

, Volume 6, Issue 3, pp 364–370

von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

Authors

  • Olivier Muller
    • Cardiovascular Center Aalst OLV Clinic
  • Jozef Bartunek
    • Cardiovascular Center Aalst OLV Clinic
  • Michalis Hamilos
    • Cardiovascular Center Aalst OLV Clinic
  • Catalina Trana Berza
    • Cardiovascular Center Aalst OLV Clinic
  • Fabio Mangiacapra
    • Cardiovascular Center Aalst OLV Clinic
  • Argyrios Ntalianis
    • Cardiovascular Center Aalst OLV Clinic
  • Kristof Vercruysse
    • Ablynx NV
  • Christian Duby
    • Ablynx NV
  • William Wijns
    • Cardiovascular Center Aalst OLV Clinic
  • Bernard De Bruyne
    • Cardiovascular Center Aalst OLV Clinic
  • Guy R. Heyndrickx
    • Cardiovascular Center Aalst OLV Clinic
  • Marc Vanderheyden
    • Cardiovascular Center Aalst OLV Clinic
  • Josefin-Beate Holz
    • Ablynx NV
    • Cardiovascular Center Aalst OLV Clinic
Article

DOI: 10.1007/s12265-012-9422-3

Cite this article as:
Muller, O., Bartunek, J., Hamilos, M. et al. J. of Cardiovasc. Trans. Res. (2013) 6: 364. doi:10.1007/s12265-012-9422-3

Abstract

ALX-0081 is a novel nano-antibody inhibiting von Willebrand factor (vWF). We evaluated whether direct inhibition of vWF by ALX-0081 improves endothelial function. Stable patients (pts, n = 55) with single vessel disease undergoing percutaneous coronary intervention (PCI) were randomized to ALX-0081 (n = 38) or placebo (n = 17). vWF inhibition was assessed by vWF antigen level (vWF:Ag) and activity by ristocetin test (vWF:RiCo). Endothelial function was assessed before (BL), 6 h and 24 h after PCI by: (a) endothelial peripheral arterial tonometry (Endoscore); (b) endothelial microparticles (EMPs) by flow cytometry. vWF:Ag and vWF:RiCo decreased within 1 h from ALX-0081. In the placebo group, no significant Endoscore changes occurred from BL to 24 h. In ALX-0081 group, Endoscore increased from BL to 24 h (p = 0.014). A decrease in EMPs was observed after ALX-0081 (p < 0.01), while no changes occurred in placebo pts. An inhibition of vWF with ALX-0081 significantly improves peripheral endothelial function.

Keywords

von Willebrand factorNano-antibodyEndothelial functionCoronary artery diseasePCI

Copyright information

© Springer Science+Business Media New York 2012